Genprex

Historical price data

Genprex is a clinical-stage biotech focused on developing gene therapies for cancer and diabetes using its proprietary Oncoprex® non-viral delivery platform. The company's strategy centers on advancing its lead candidate, REQORSA, through mid-stage trials in non-small cell and small cell lung cancer, with programs supported by multiple FDA Fast Track and Orphan Drug designations. While still pre-revenue, Genprex aims to address large, underserved patient populations by combining its platform technology with established therapies to overcome treatment resistance.

Proprietary non-viral Oncoprex® Nanoparticle Delivery System for systemic gene delivery in oncology, and an AAV-based vector for pancreatic gene delivery in diabetes.

In oncology, Genprex's non-viral tumor suppressor gene delivery is a key differentiator in a field dominated by viral therapies, cell therapies, and small molecules. In diabetes, its transdifferentiation approach competes with emerging cell replacement and gene editing therapies.